JPMorgan analyst Rohin Patel initiated coverage of Haemonetics (HAE) with an Overweight rating and $116 price target Haemonetics has “multiple shots on goal” that should support sales acceleration and healthy cash flow generation over the coming years as the mix shifts to premium, higher margin interventional products, and the commercial plasma business normalizes, the analyst tells investors in a research note. The firm thinks a “strong” fiscal Q2 and underlying business trends should support high-20%’s operating margin next year, with further upside thereafter.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HAE:
- Haemonetics to sell whole blood assets to GVS for $44.6M upfront
- Haemonetics management to meet virtually with BTIG
- Haemonetics added to Analyst Current Favorites list at Raymond James
- Haemonetics upgraded to Strong Buy from Outperform at Raymond James
- Haemonetics’ Q2 2025 Earnings Show Strong Growth
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
